AA
Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS)
₹116.03
Mkt cap
₹343 Cr
P/E ratio
76.00
P/B
2.18
Div yield
0.00%
ROE
2.75%
ROCE
5.58%
EPS (TTM)
₹1.53
Book value
₹53
52W range
50–117
Sector
Healthcare
Price history
Previous close
Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse industrial applications [1]
NSE AAREYDRUGSBSE 524412
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBullish
52-week range
−0.74% from high₹116
₹50+130.63% from low₹117
Current
₹116.03
Prev close
₹112.20
Day
+3.41%
Price performance
1D
+3.30%
1W
+0.65%
1M
+4.97%
3M
+43.81%
6M
+41.29%
1Y
+20.73%
YTD
+74.90%
Financials
Revenue, profit & margin
P/E ratio
76.0×
AAREYDRUGS is 132% above the sector median of 32.8×
AAREYDRUGS76.0×
Sector median32.8×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57.83 | 76.48 | 210.35 | 126.91 | 105.14 | 133.79 | 108.10 | 102.21 | 84.16 | 96.43 | 189.47 | 44.63 | 88.62 | |
| YoY Sales growth | -24.17% | +22.43% | +29.14% | +149.04% | +81.81% | +74.93% | -48.61% | -19.46% | -19.95% | -27.92% | +75.27% | -56.33% | +5.30% | |
| Expenses | 55.99 | 73.78 | 211.79 | 125.73 | 101.42 | 131.59 | 112.31 | 100.50 | 81.52 | 97.94 | 185.13 | 43.31 | 86.48 | |
| Operating Profit | 1.84 | 2.70 | -1.44 | 1.18 | 3.72 | 2.20 | -4.21 | 1.71 | 2.64 | -1.51 | 4.34 | 1.32 | 2.14 | |
| OPM % | 3.18% | 3.53% | -0.68% | 0.93% | 3.54% | 1.64% | -3.89% | 1.67% | 3.14% | -1.57% | 2.29% | 2.96% | 2.41% | |
| Other Income | 0.84 | 0.29 | 5.14 | 1.58 | 0.02 | 0.68 | 7.54 | 1.55 | 0.79 | 4.18 | -0.43 | 1.72 | 1.62 | |
| Interest | 0.41 | 0.47 | 0.40 | 0.96 | 0.49 | 0.58 | 1.30 | 1.04 | 1.26 | 0.92 | 1.78 | 1.67 | 1.16 | |
| Depreciation | 1.27 | 1.06 | 1.15 | 0.47 | 1.51 | 0.90 | 0.41 | 0.49 | 0.69 | 0.83 | 0.85 | 0.85 | 0.94 | |
| Profit before tax | 1.00 | 1.46 | 2.15 | 1.33 | 1.74 | 1.40 | 1.62 | 1.73 | 1.48 | 0.92 | 1.28 | 0.52 | 1.66 | |
| Tax % | -22.00% | 30.14% | -0.47% | 6.77% | 8.62% | 48.57% | 71.60% | 20.81% | 31.08% | 38.04% | -21.88% | -98.08% | 17.47% | |
| Net Profit | 1.23 | 1.02 | 2.15 | 1.24 | 1.60 | 0.72 | 0.47 | 1.37 | 1.02 | 0.57 | 1.56 | 1.02 | 1.37 | |
| EPS in Rs | 0.48 | 0.40 | 0.77 | 0.44 | 0.57 | 0.25 | 0.17 | 0.48 | 0.36 | 0.20 | 0.55 | 0.36 | 0.43 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +2.04% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 14 Aug '26◦ |
| Earnings day | +2.04% |
| +1 day | −2.04% |
| +5 days | −6.88% |
| +15 days | +16.02% |
| +30 days | +19.14% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202641.46%Promoter
Promoters41.46%3.75
FIIs4.28%0.53
DIIs1.44%0.18
Public52.83%3.04
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,871.50 | 36.49 | 4,49,036 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,049.00 | 85.83 | 2,93,316 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,610.70 | 80.78 | 1,75,376 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,322.50 | 93.66 | 1,25,488 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,202.00 | 26.46 | 1,19,900 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,398.20 | 41.71 | 1,16,788 | 0.57% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,417.00 | 36.86 | 1,14,478 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Aarey Drugs | ₹107.75 | 75.98 | 343 | 0.00% | 1 | +34.31% | 89 | +5.30% | 5.58% |
| Median: 160 Co. | ₹439.32 | 32.75 | 2,001 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Nov - Pursuant to Regulation 47 of SEBI (LODR) Regulation, 2015, the company has published and extract of statement of unaudited standalone Financial ....Statement Of Deviation And Variation For The Quarter Ended September 30, 2026 14 Nov - Aarey Drugs reports no deviation in warrant proceeds; ₹2,481.82 lakh received, ₹900 lakh unutilised as of 30 Sep 2026.Unaudited Financial Results For The Second Quarter & Half Year Ended On 30Th September, 2026 14 NovBoard Meeting Outcome for Outcome Of Board Meeting Held On November 14, 2026 14 Nov - Board approved Q2/H1 FY2026-27 results and no deviation in warrant proceeds use.Board Meeting Intimation for Approving The Un-Audited Financial Results For The Quarter And Half Year Ended On 30.09.2026 6 Nov - Board meeting on 14 Nov 2026 to approve Q2 and half-year unaudited results.






